Reuters logo
BRIEF-Astrazeneca says Faslodex receives US FDA approval for treatment of advanced breast cancer in combination with abemaciclib
November 15, 2017 / 7:41 AM / 4 days ago

BRIEF-Astrazeneca says Faslodex receives US FDA approval for treatment of advanced breast cancer in combination with abemaciclib

Nov 15 (Reuters) - ASTRAZENECA PLC:

* ‍US FOOD AND DRUG ADMINISTRATION (FDA) HAS APPROVED A NEW INDICATION FOR FASLODEX (FULVESTRANT)​

* ‍FASLODEX IN COMBINATION WITH ABEMACICLIB SHOWED 16.4 MONTHS OF PROGRESSION-FREE SURVIVAL​ Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below